EP2 and EP4 prostanoid receptor signaling

Life Sciences

Volumn 74, Issue 2-3, 2003, Pages 143-153

  Regan, John W ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

cAMP; Cancer; G protein coupled receptors; PGE2; Prostaglandins

Indexed keywords

7 [3 HYDROXY 2 [3 HYDROXY 4 (3 METHOXYMETHYLPHENYL) 1 BUTENYL] 5 OXOCYCLOPENTYL] 5 THIAHEPTANOIC ACID METHYL ESTER; BIPHENYLOXAZOLE; BUTAPROST; CP 533536; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EARLY GROWTH RESPONSE FACTOR 1; G PROTEIN COUPLED RECEPTOR; L 161982; MITOGEN ACTIVATED PROTEIN KINASE 1; ONO AE 1 259; ONO AE 1 329; ONO AE 2 227; OXAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN EP2 RECEPTOR; PROSTAGLANDIN EP4 RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; PROSTAGLANDIN E2 RECEPTOR, EP4 SUBTYPE;

CONFERENCE PAPER; GENE DELETION; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; WOUND HEALING; AMINO ACID SEQUENCE; ANIMAL; GENETICS; MOLECULAR GENETICS; MOUSE; MOUSE MUTANT; PHYSIOLOGY; REVIEW; SECOND MESSENGER;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; RECEPTORS, PROSTAGLANDIN E; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION;

EID: 0242321274     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.09.031     Document Type: Conference Paper

References (43)

1. 2. Biochem. Biophys. Res. Commun. 197:1993;263-270.
2. Araki Y., Okamura S., Hussain S.P., Nagashima M., He P., Shideki M., Miura K., Harris C.C. Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways. Cancer Res. 63:2003;728-734.
3. Cadigan K.M., Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 11:1997;3286-3305.
4. Coleman R.A., Grix S.P., Head S.A., Louttit J.B., Mallett A., Sheldrick R.L.G. A novel inhibitory receptor in piglet saphenous vein. Prostaglandins. 47:1994;151-168.
5. Coleman R.A., Smith W.L., Narumiya S. VIII. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-229.
6. 4 receptor sequestration. Mol. Pharmacol. 58:2000;1279-1286.
7. Fujino H., Regan J.W. Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer. Trends Pharmacol. Sci. 24:2003;335-340.
8. 2. J. Biol. Chem. 277:2002;2614-2619.
9. 2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J. Biol. Chem. 278:2003;12151-12156.
10. 2 agonists or antagonists. Patent WO0018744.
11. 2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J. Leuko. Biol. 73:2003;756-763.
12. 2. Proc. Natl. Acad. Sci. USA. 96:1999;10501-10506.
13. 2 subtype. J. Biol. Chem. 268:1993;7759-7762.
14. Kamei D., Murakami M., Nakatani Y., Ishikawa Y., Ishii T., Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J. Biol. Chem. 278:2003;19396-19405.
15. 2 prostaglandin receptor confers responsiveness to prostacyclin analogs. Mol. Pharmacol. 54:1998;584-590.
16. 2 receptor. Nat. Med. 5:1999;217-220.
17. Kobayashi T., Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglan. Other Lipid Mediat. 68-69:2002;557-573.
18. 2 receptor impairs osteoclastogenesis in vitro. Endocrinology. 141:2000;2054-2061.
19. 2. Mol. Pharmacol. 60:2001;36-41.
20. 2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 110:2002;651-658.
21. 2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 275:2000;32783-32792.
22. 4 in colon carcinogenesis. Cancer Res. 62:2002;28-32.
23. 2 synthase gene. Essential role of the transcription factor Egr-1. J. Biol. Chem. 277:2002;28601-28608.
24. Narumiya S., FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108:2001;25-30.
25. 2 that regulate cellular immune responses in the mouse. J. Clin. Invest. 108:2001;1229-1235.
26. Nguyen M., Camenisch T., Snouwaert J.N., Hicks E., Coffman T.M., Anderson P.A.W., Malouf N.N., Koller B.H. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature. 390:1997;78-81.
27. 4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol. Pharmacol. 50:1996;1031-1037.
28. 4 on hyperalgesia and inflammation in monoarthritic model. Anesthesiology. 97:2002;170-176.
29. 2 agonist induces bone healing. Proc. Natl. Acad. Sci. USA. 100:2003;6736-6740.
30. 2 subtype. Mol. Pharmacol. 46:1994;213-220.
31. 4 subtype. Infect. Immun. 68:2000;6819-6825.
32. Δ716 mouse intestinal polyps. Cancer Res. 62:2002;506-511.
33. 2 in mice. J. Appl. Physiol. 88:2000;2214-2218.
34. 2: studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem. Pharmacol. 61:2001;1153-1160.
35. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69:2000;145-182.
36. Δ716 knockout mice. Nat. Med. 7:2001;1048-1051.
37. 4 receptors is required for ligand binding. Eur. J. Pharmacol. 357:1998;73-82.
38. 3 subtype. J. Biol. Chem. 267:1992;6463-6466.
39. 2 suppresses chemokine production in human macrophages through the EP4 receptor. J. Biol. Chem. 277:2002;44147-44154.
40. Toh H., Ichikawa A., Narumiya S. Molecular evolution of receptors for eicosanoids. FEBS Letters. 361:1995;17-21.
41. 1 subtype of prostaglandin E receptor. J. Biol. Chem. 268:1993;20175-20178.
42. Yang L., Yamagata N., Yadav R., Brandon S., Courtney R.L., Morrow J.D., Shyr Y., Boothby M., Joyce S., Carbone D.P., Breyer R.M. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111:2003;727-735.
43. 4 receptor activation. Proc. Natl. Acad. Sci. USA. 99:2002;4580-4585.